Organizers of the 63rd Annual American Society of Hematology Meeting and Exposition have multiple safety precautions in place to host a hybrid meeting in Atlanta December 11-14.
In recent weeks, the scientific meeting circuit has crept back to life from the COVID-19 pandemic. But the biggest test to date will come this weekend in Atlanta, when the 63rd American Society of Hematology (ASH) Meeting and Exposition gathers December 11-14 at the Georgia World Congress Center, with a virtual format option for those who prefer to participate remotely.
Organizers do not expect the meeting to draw the 30,000 attendees who descended on Orlando, Florida, in 2019 for the last in-person ASH gathering. How many will see the science in person—and catch up with colleagues after nearly 2 years—is anyone’s guess, with the Omicron variant throwing a late curveball into everyone’s plans. The ASH website states that both in-person and online registration “remains strong.”
ASH President Martin S. Tallman, MD, who is professor of medicine at Weill Cornell Medical College and the chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City, said the decision to hold the hybrid event was made with careful consideration, based on surveys of ASH members.
“While we do not expect a pre-2020 level of attendance, there is still a significant portion of the community that is enthusiastic about a return to in-person meetings, and we are confident that we can deliver that experience in a safe and thoughtful way,” Tallman wrote in a premeeting message that appeared in The Hematologist.
ASH organizers are taking precautions to keep attendees safe. Proof of vaccination is required before attendees can travel to Atlanta, and masks must be worn. No on-site registration is permitted.
Therapeutic Advances, Led by CAR T-Cell Therapy
There’s plenty of great science to draw people to Atlanta, led by results from multiple trials that examine the use of CAR T-cell therapy in second-line or even first-line use in the treatment of large B-cell lymphoma (see related article).
ASH organizers also highlighted presentations by L. Elizabeth Budde, MD, PhD, of City of Hope, who will present phase 1/2 results for mosunetuzumab for patients with relapsed or refractory follicular lymphoma who have had at least 2 lines of therapy, and phase 3 results from Hartmut Goldschmidt, MD, of Heidelberg Hospital, on adding isatuximab to lenalidomide, bortezomib, and dexamethasone for patients with newly diagnosed multiple myeloma.
Noteworthy therapeutic results to be presented at ASH include:
Effects of COVID-19 and Vaccines
Last year’s online meeting came days before FDA granted Pfizer the first emergency use authorization (EUA) for a COVID-19 vaccine, and the big question was whether patients with blood cancers and disorders should take it. Not only was the answer yes, but they should get at the front of the line, experts said. Even if the response was minimal, it was better than nothing.
Now, 21 months into the pandemic, investigators will present data to answer questions on blood disorders, COVID-19, and vaccines:
A basic science abstract that Jacob G. Ludington, MD, PhD, of Beth Israel Deaconess Medical Center, Boston, will present during the plenary session will examine how a mechanism associated with SARS-CoV-2 can lead to blood clots.
And with Atlanta being home to the CDC, the public health agency’s director, Rochelle Walensky, MD, MPH, will lead an event billed as a “Grassroots Network Lunch” on Saturday at the Omni Atlanta Hotel.
Health Equity and Disparities
The pandemic has brought disparities in cancer care and outcomes into focus, and multiple sessions at ASH address the effect on patients with blood cancers and disorders. A group of these abstracts were highlighted in a press preview call by Tallman.
Lori Muffly, MD, of Stanford Medical Center, will present data Saturday on disparities in enrollment in clinical trials involving adolescents and young adults with acute lymphoblastic leukemia (AML). “In addition to disparities in outcome, there are also disparities simply in enrollment onto clinical trials,” said Tallman. “It's found that 40% of adolescent and young adults in the United States with AML are Hispanic and 7% are Black.”
However, fewer Hispanic patients were enrolled on a major clinical trial than are represented in the US population—which was not a complete surprise, since the trial was not even available in several states with high numbers of Hispanic patients.
Saturday will also bring the first results of the PROMISE Study, which uses screening for monoclonal gammopathy to identify individuals at high risk of multiple myeloma and has the largest cohort of Black enrollees, a group at high risk of the disease.
A special scientific session on race and science is scheduled for Saturday at 4 pm.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More